Female Infertility: Global Opportunity Analysis & Forecast, 2019-2028 - ResearchAndMarkets.com

DUBLIN--()--The "Female Infertility: Opportunity Analysis and Forecasts to 2028" report has been added to ResearchAndMarkets.com's offering.

This report expects the Female Infertility (FI) drug market to grow from $1.8bn in 2018 to $2.5bn in 2028 across the seven major markets (7MM - US, France, Germany, Italy, Spain, the UK and Japan) at a compound annual growth rate (CAGR) of 3.4%. This growth will be partially attributed to the projected increase in assisted reproductive technology (ART) treatment rates in the seven major markets (7MM - US, France, Germany, Italy, Spain, the UK and Japan) during the forecast period.

Female Infertility (FI) is a complex disorder defined as the inability to conceive after at least one year of timed, unprotected intercourse. The etiology of the condition spans a wide range of disorders that can be broadly classified into the following categories: diminished ovarian reserve & ovulation disorders, endometriosis, fallopian tube abnormalities, uterine factors and unexplained infertility.

The fact that a growing number of women are postponing pregnancy until later in life when fertility has generally decreased, will translate into increased use of ART fertility treatments between 2018 and 2028.

A limited number of established companies compete in this space, and the strategy has mainly been to create improved versions of existing drugs. As such, the drugs used to treat patients have remained largely unchanged. These include, among others, blockbuster drugs such as EMD Serono's Gonal-F (follitropin alfa), Merck & Co's Follistim (follitropin beta) and Ferring Pharmaceuticals' Menopur (menotropins) which collectively claimed over 50% of the total FI market in 2018.

Among the late stage pipeline agents, key opinion leaders (KOLs) interviewed by the author were especially enthusiastic regarding nolasiban, noting a promising future for the drug in the ART treatment setting. In 2028, this drug will be worth $320m in the US and 5EU (France, Germany, Italy, Spain and the UK). Ultimately, nolasiban will be a welcome addition to the therapeutic paradigm that will partially address the unmet need of improving embryo implantation rates during ART cycles.

Of particular note are the unmet needs for treatments that further improve success rate per ART cycle, orally and less frequently administered drugs during in vitro fertilization (IVF) treatment, novel treatments for improving IVF outcomes in reproductively older women and reducing the high IVF treatment dropout rates.

Scope

  • Overview of Female Infertility including epidemiology, etiology and current treatment options, namely ovulation induction and ART
  • Topline Female Infertility market revenue, annual cost of therapy, and major pipeline product sales in the forecast period.
  • Key topics covered include current treatment and pipeline therapies, unmet needs and opportunities, and the drivers and barriers affecting Female Infertility therapeutics sales in the 7MM.
  • Pipeline analysis: Comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
  • Analysis of the current and future market competition in the global Female Infertility therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

The report will enable you to:

  • Develop and design your in-licensing and out-licensing strategies, using a detailed overview of current pipeline products and technologies to identify companies with the most robust pipelines.
  • Develop business strategies by understanding the trends shaping and driving the global Female Infertility therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global Female Infertility market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Track drug sales in the global Female Infertility therapeutics market from 2018-2028.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Companies Mentioned

  • Merck KGaA
  • Merck & Co
  • Ferring International
  • Myovant Sciences
  • ObsEva
  • Richter Gedeon
  • AbbVie
  • Teva Pharmaceutical Industries
  • Pfizer
  • IBSA Farmaceutici Italia
  • ASKA Pharmaceutical
  • Allergan

Key Topics Covered

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Female Infertility: Executive Summary

2.1 Moderate Growth in the Female Infertility Market Expected Between 2018 and 2028, Driven by US and EU Sales

2.2 R&D Strategies Focused Largely on Improved Versions of Current Drugs

2.3 Despite Major Progress in Treating Patients, Unmet Needs Exists in the Space

2.4 Sparse Pipeline, But Potential New Addition Highly Intriguing to Physicians

2.5 What Do Physicians Think?

3 Introduction

3.1 Catalyst

3.2 Related Reports

4 Disease Overview

4.1 Etiology

4.1.1 Diminished Ovarian Reserve & Ovulation Disorders

4.1.2 Endometriosis

4.1.3 Fallopian tube abnormalities/pelvic adhesions

4.1.4 Uterine factors

4.1.5 Unexplained infertility

4.1.6 Other factors

5 Epidemiology

5.1 Disease Background

5.2 Risk Factors and Comorbidities

5.3 Global and Historical Trends

5.4 Forecast Methodology

5.4.1 Sources Used

5.4.2 Forecast Assumptions and Methods: Total Prevalent Cases of Female Infertility and Impaired Fecundity

5.4.3 Forecast Assumptions and Methods: Total Prevalence of Female Infertility by Major Etiological Factors

5.4.4 Forecast Assumptions and Methods: Total Prevalence of Impaired Fecundity by Treatment Type

5.5 Epidemiological Forecast for Female Infertility and Impaired Fecundity (2018-2028)

5.5.1 Total Prevalent Cases of Female Infertility

5.5.2 Total Prevalent Cases of Impaired Fecundity

5.5.3 Age-Specific Total Prevalent Cases of Female Infertility

5.5.4 Age-Specific Total Prevalent Cases of Impaired Fecundity

5.5.5 Total Prevalent Cases of Female Infertility by Major Etiological Factors

5.6 Discussion

5.6.1 Epidemiological Forecast Insight

5.6.2 Limitations of the Analysis

5.6.3 Strengths of the Analysis

6 Current Treatment Options

6.1 Overview

6.2 Ovulation Induction

6.2.1 Clomiphene Citrate

6.2.2 Aromatase Inhibitors

6.2.3 Gonadotropins

6.3 Assisted Reproductive Technologies

6.3.1 Gonadotropins

6.3.2 GnRH Agonists

6.3.3 GnRH Antagonists

7 Unmet Needs and Opportunity Assessment

7.1 Overview

7.2 Improved IVF Success Rates Per Cycle

7.3 Oral and Longer-Acting Drugs that Simplify the IVF Process

7.4 Patient-Friendlier Progesterone Administration for Luteal Phase Support

7.5 Novel Treatments for Poor Responders

7.6 Non-Surgical Treatments for Uterine Fibroid-Related Infertility

7.7 Reducing High IVF Treatment Patient Dropout Rates

7.8 Early Detection of High-Risk Patients

8 R&D Strategies

8.1 Overview

8.1.1 Long-Acting FSH Analogue

8.1.2 Pre-Filled Pen Injection Devices

8.1.3 Fixed Combination of Follitropin Alfa + Lutropin Alfa

8.2 Clinical Trials

8.2.1 Current Clinical Trial Design

8.2.2 Incomplete Reporting of Outcomes

9 Pipeline Assessment

9.1 Overview

9.2 Promising Drugs in Clinical Development

9.2.1 Nolasiban (OBE001)

9.2.2 MVT-602

9.2.3 Milprosa (DR-2011, Progesterone Vaginal Ring)

9.2.4 Off-Label Potential for Oral GnRH Antagonists

9.3 Other Drugs in Development

10 Pipeline Valuation Analysis

10.1 Clinical Benchmark of Key Pipeline Drugs

10.1.1 Nolasiban

10.1.2 MVT-602

10.1.3 Milprosa

10.2 Commercial Benchmark of Key Pipeline Drugs

10.3 Competitive Assessment

10.4 Top-Line 10-Year Forecast

10.4.1 US

10.4.2 5EU

10.4.3 Japan

For more information about this report visit https://www.researchandmarkets.com/r/ucudhk

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900